Compare WMK & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMK | NRIX |
|---|---|---|
| Founded | 1912 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 1994 | 2020 |
| Metric | WMK | NRIX |
|---|---|---|
| Price | $67.93 | $15.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $30.58 |
| AVG Volume (30 Days) | 136.1K | ★ 968.3K |
| Earning Date | 03-12-2026 | 04-10-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.65 | N/A |
| Revenue | ★ $4,714,573,000.00 | $76,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.32 |
| P/E Ratio | $18.75 | ★ N/A |
| Revenue Growth | 0.01 | ★ 99.31 |
| 52 Week Low | $59.99 | $8.18 |
| 52 Week High | $90.23 | $22.50 |
| Indicator | WMK | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 54.71 | 50.50 |
| Support Level | $68.06 | $14.61 |
| Resistance Level | $70.31 | $16.47 |
| Average True Range (ATR) | 1.84 | 0.89 |
| MACD | 0.53 | 0.07 |
| Stochastic Oscillator | 82.41 | 66.97 |
Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products mainly belong to the following categories: center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.